David Goldfarb, PhD, MPH

Landmark Science, Inc

Poster(s):

• (B-032) Characteristics of Patients Initiating Glucagon-like Peptide-1 (GLP-1) Receptor Agonists (RAs) for Cardiometabolic Risk Reduction in a Medicare Population
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (B-033) Characteristics of Patients Initiating Wegovy (Semaglutide) for Cardiovascular Risk Reduction in a Medicare Population
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (B-079) Characteristics of RWE used in Regulatory Decision-Making for Marketing Authorization Applications (MAAs)
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (B-080) Evaluation of Real-World Evidence in Regulatory and HTA Submissions
  Monday, August 25, 2025

  11:30 AM - 1:00 PM ET

• (C-124) Framework for Real-World Data Used in Regulatory Submissions
  Tuesday, August 26, 2025

  12:00 PM - 1:30 PM ET